###begin article-title 0
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">*</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2">S&#8414;</xref>
###xml 6 11 <span type="species:ncbi:9606">Human</span>
Novel Human Glioma-associated Oncogene 1 (GLI1) Splice Variants Reveal Distinct Mechanisms in the Terminal Transduction of the Hedgehog Signal*Sâƒž
###end article-title 0
###begin p 1
###xml 112 129 112 129 <email xmlns:xlink="http://www.w3.org/1999/xlink">tash@biosci.ki.se</email>
###xml 131 132 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 221 235 221 235 <email xmlns:xlink="http://www.w3.org/1999/xlink">peza@cnt.ki.se</email>
 Supported by a Marie Curie International Incoming Fellowship. To whom correspondence may be addressed. E-mail: tash@biosci.ki.se. 3 To whom correspondence may be addressed: Tel.: 46-8-6089151; Fax: 46-8-6081501; E-mail: peza@cnt.ki.se.
###end p 1
###begin p 2
These authors contributed equally to this work.
###end p 2
###begin p 3
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 3
###begin p 4
 applies to Author Choice Articles
###end p 4
###begin p 5
###xml 518 523 <span type="species:ncbi:9606">human</span>
Hedgehog (HH) signaling is one of the key pathways with major significance for embryogenesis, tumorigenesis, and stem cell maintenance. Glioma-associated oncogene 1 (GLI1) is a transcription factor that acts as the terminal signaling effector but also represents a pathway target gene. Here we report the identification and functional properties of novel GLI1 splice variants generated by skipping exons 2 and 3 and encoding an N-terminal truncated GLI1 protein (GLI1DeltaN). Analysis of the GLI1DeltaN mRNAs in adult human tissues revealed comparable expression levels to the full-length GLI1 (GLI1FL), whereas in tumor cell lines a generally lower and more variable expression pattern was observed. Furthermore, GLI1DeltaN is up-regulated by HH signaling to the same extent as GLI1FL but has a weaker capacity to activate transcription. However, in specific cellular contexts GLI1DeltaN may be more potent than GLI1FL in activating endogenous gene expression. Moreover, the dual-specificity tyrosine phosphorylation-regulated kinase 1 (Dyrk1) potentiates the transcriptional activity of GLI1FL but not GLI1DeltaN. Interestingly, GLI1FL, in contrast to GLI1DeltaN, is localized solely at the nucleus, in line with its increased transcriptional capacity. The negative regulator of the pathway, Suppressor of Fused (SUFU), elicits a cytoplasmic retention of the GLI1 isoforms, which is more pronounced for GLI1FL, as this contains an N-terminal SUFU binding domain. Collectively, our findings reveal that the activation mechanism of the terminal transducer of the pathway, GLI1, is mediated not only by GLI1FL but also by the GLI1DeltaN variant.
###end p 5
###begin p 6
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 6
###begin p 7
###xml 39 58 39 58 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Swedish Cancer Fund</grant-sponsor>
###xml 64 88 64 88 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Swedish Research Council</grant-sponsor>
###xml 98 114 98 114 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Magnus Bergvalls</grant-sponsor>
###xml 119 164 119 164 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Anders Otto Sw&#228;rds/Ulrika Eklunds foundations</grant-sponsor>
###xml 307 320 307 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported in part by the Swedish Cancer Fund, the Swedish Research Council, and the Magnus Bergvalls and Anders Otto Swards/Ulrika Eklunds foundations. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 7
###begin p 8
The on-line version of this article (available at ) contains supplemental Table S1 and Figs. S1-S7.
###end p 8
###begin p 9
###xml 0 180 0 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">The nucleotide sequence(s) reported in this paper has been submitted to the GenBank&#8482;/EBI Data Bank with accession number(s) AB239136 (GLI1 E1&#8211;4) and AB239328 (GLI1 E1A-4).</italic>
The nucleotide sequence(s) reported in this paper has been submitted to the GenBanktrade mark/EBI Data Bank with accession number(s) AB239136 (GLI1 E1-4) and AB239328 (GLI1 E1A-4).
###end p 9
###begin p 10
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 700 701 700 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 234 239 <span type="species:ncbi:9606">human</span>
###xml 502 507 <span type="species:ncbi:9606">human</span>
The post-transcriptional process of alternative splicing is considered to be a pervasive phenomenon in eukaryotic gene expression that increases the diversity of mRNAs and proteins. Genome-wide analysis indicates that at least 75% of human multiexon genes have alternative splice variants (1, 2). Additionally, variations in the splicing pattern of gene products have been related to pathological states including cancer. It is now believed that a minimum of 15% of the point mutations responsible for human genetic diseases are in fact interfering with splicing regulatory events (3, 4). Alternative splice variants have the potential of being used as diagnostic markers and/or therapeutic targets (5).
###end p 10
###begin p 11
###xml 17 18 17 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn4">4</xref>
###xml 127 137 127 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 382 383 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 394 404 394 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 817 836 817 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cubitus interruptus</italic>
###xml 1345 1347 1345 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref10">10</xref>
###xml 1349 1351 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 127 137 <span type="species:ncbi:7227">Drosophila</span>
###xml 394 404 <span type="species:ncbi:7227">Drosophila</span>
The Hedgehog (HH)4 signaling pathway was first reported as a major pathway involved in pattern formation during development of Drosophila and embryonic developmental processes in vertebrates. Additionally, abnormal activation of the pathway has been linked to several cancers including basal cell carcinoma, medulloblastoma, rhabdomyosarcoma, lung, prostate, and pancreatic tumors (6-9). Using Drosophila as the model organism significant findings on the mechanism of this pathway have been revealed. Active signal transduction is generally associated with binding of HH ligands to the Patched (PTCH) receptor. This releases the inhibitory effects of PTCH on the signaling molecule Smoothened (SMO), thus initiating a series of molecular events that lead to up-regulation of target genes by the transcription factor, Cubitus interruptus (Ci). However, in mammals gene duplications of many signaling components have resulted in increased complexity. The three HH (Sonic, Desert, and Indian HH), the two PTCH (PTCH1 and PTCH2), and the three Ci (GLI1, GLI2, and GLI3) orthologues have different biological functions and tissue distributions. Interestingly, the negative regulator of the pathway, PTCH1, its paralogue, PTCH2, and the positive regulator, GLI1, are all up-regulated by HH signaling resulting in negative and positive feedback loops (10, 11).
###end p 11
###begin p 12
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 702 704 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref19">19</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
Recent studies indicate that variations in the choice of exons that are included in the mature, spliced mRNA molecules do occur in molecular components of the HH signaling pathway. PTCH1 and PTCH2 variants characterized by alternative first exons, exon skipping/inclusion, and/or alternative terminal exons have been identified (12-15). Interestingly, some but not all of the alternative first exon variants of PTCH1 are up-regulated by HH signaling. These up-regulated variants are the ones with the strongest capacity to inhibit signal transduction and act therefore as the main mediators of the negative feedback (16). The transcription factor GLI2 is also characterized by several splice variants (17-19). Moreover, the significance of such variations in pathway components is corroborated by a genome-wide RNA interference screen that identified a large number of splicing and RNA-regulatory proteins that modulate HH signaling (20).
###end p 12
###begin p 13
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLI1</italic>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 266 281 <span type="species:ncbi:10090">transgenic mice</span>
Glioma-associated oncogene 1 (GLI1) is a transcription factor, which acts as a terminal effector of the HH signaling pathway, in addition to being a target gene (21). GLI1 has been characterized as an oncogene and its overexpression leads to basal cell carcinoma in transgenic mice (22). Moreover, it also acts as a key molecule in the regulation of glioma growth and the self-renewal of cancer stem cells (23, 24). Additionally, Wang and Rothnagel (25) have identified splice variants in the 5' noncoding region of GLI1. In this report we provide evidence for splicing variations that alter the coding sequence of GLI1. These variants lack an interaction domain with the negative regulator of the pathway, Suppressor of Fused (SUFU) (26), and have unique capacities in activating transcription of target genes.
###end p 13
###begin title 14
EXPERIMENTAL PROCEDURES
###end title 14
###begin p 15
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tissue Distribution Analysis</italic>
###xml 313 314 313 314 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 335 336 334 335 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 474 475 472 473 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 552 555 549 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
Tissue Distribution Analysis-PCR primer pairs were designed for both alternative first exons of GLI1. Multiple tissue cDNA panels from BD Biosciences were used with the primers obtained from MWG-Biotech (Ebersberg, Germany). Each reaction consisted of 1x ThermoPol Reaction buffer (New England Biolabs, MA), 0.2 mm of each dNTP, 1.0 mum forward primer for the alternative first exons (5'-GAGCCCAGCGCCCAGACAGA for exon 1 or 5'-CTGTCTCAGGGAACCGTGGGTCTTTGT for exon 1A), 1.0 mum reverse primer for exon 4 (5'-GGCATCCGACAGAGGTGAGATGGAC), 0.05 units/mul of Taq DNA polymerase (New England Biolabs), and 1 ng of cDNA in a total volume of 25 mul. Thirty-five cycles with 20 s at 94 degreesC, 20 s at 66 degreesC, and 30 s at 72 degreesC were performed on a PTC-200 Peltier Thermal Cycler (MJ Research, MA). Amplifications without exogenous cDNA were used in all sets of experiments as a negative control. The PCR products were analyzed on a 4% NuSieve 3:1 agarose gel (FMC BioProducts, ME). All DNA bands were sequence verified by using BigDye Terminator version 1.1 Cycle Sequencing Kits and an ABI prism DNA sequencer (Applied Biosystems, CA).
###end p 15
###begin p 16
###xml 0 26 0 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cDNA Expression Constructs</italic>
###xml 868 870 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
cDNA Expression Constructs-For construction of the GLI1DeltaN expression plasmid, we first performed a PCR amplification using the Expand PCR System (Roche Diagnostics) on cDNA from HEK293 cells, which express this variant, and a GLI1 primer set (5'-CTCAAGCTTGGCACCATGAGCCCAT and 5'-CACAGATTCAGGCTCACGCTTC). The PCR product and a full-length 3'-FLAG-tagged GLI1 expression plasmid in pCMV5 were digested with HindIII and XhoI restriction enzymes and then ligated resulting in a construct with deleted exons 2 and 3. Additionally, SalI- and BglII-digested FLAG-tagged GLI1FL or GLI1DeltaN fragments were subcloned into SalI- and BamHI-digested pBABEpuro. The 3'-GFP-tagged GLI1FL and GLI1DeltaN constructs were generated from the HindIII and NdeI fragments of FLAG-tagged GLI1FL/GLI1DeltaN expression plasmids in pCMV5, the NdeI and NotI fragments of EGFP-tagged GLI1 (27), and the HindIII and NotI fragments of pEGFP-N3 (BD Biosciences). All constructs were verified by sequencing.
###end p 16
###begin p 17
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTCH2</italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 373 378 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R2</italic>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch1</italic>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn5">5</xref>
###xml 395 400 <span type="species:ncbi:10090">mouse</span>
The other expression and reporter constructs used have been described in previous reports, the full-length 3'-FLAG-tagged PTCH1 constructs with the alternative first exons, 1, 1B, and 1C (12), 5'-Myc-tagged PTCH1 with the alternative first exon 1B (28), PTCH2 (13), Dyrk1WT, Dyrk1KR (27), and the SUFU expression constructs (29), and the 12xGLIBS-luc (29), PTCH2-luc (13), IL1R2-luc (30), and a mouse Ptch1-1B-luc5 reporter construct.
###end p 17
###begin p 18
###xml 0 29 0 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cell Culture and Transfection</italic>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 82 88 <span type="species:ncbi:10090">murine</span>
###xml 176 181 <span type="species:ncbi:9606">Human</span>
###xml 1059 1065 <span type="species:ncbi:9913">bovine</span>
Cell Culture and Transfection-The human embryonic kidney cell line HEK293 and the murine fibroblast cell lines NIH3T3 and C3H10T1/2 were cultured as described before (12, 13). Human fibroblast cell line hTERT-BJ1 (BD Biosciences), medulloblastoma cell line Daoy, which stably expresses EGFP (EGFP-Daoy), rhabdomyosarcoma cell lines RMS13 and CCA, prostate carcinoma cell lines DU145 and 22Rv1, pancreas carcinoma cell line Panc1, gastric adenocarcinoma cell line AGS, lung adenocarcinoma cell lines H22 and H522, and lung carcinoma cell line A549 were cultured according to the ATCC-LGC Promochem (Middlesex, United Kingdom) and Metalab (Bologna, Italy) recommendations. Expression constructs for the GLI1 splice variants and other pathway components, and the appropriate reporter construct were transfected into cultured cells using FuGENE 6 (Roche Diagnostics). For selection, NIH3T3 and C3H10T1/2 cells were co-transfected with the neomycin-resistant pcDNA3.1His (Invitrogen) and then incubated with Dulbecco's modified Eagle's medium containing 10% fetal bovine serum with 0.6 mg/ml G418 (Sigma).
###end p 18
###begin p 19
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Reporter Assays</italic>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch</italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTCH2</italic>
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R2</italic>
Reporter Assays-Reporter assays were performed as described previously (12, 13). 12xGLIBS-luc, Ptch-1B-luc, PTCH2-luc, or IL1R2-luc reporter constructs together with the internal control, pRL-SV (Promega) were co-transfected into the appropriate cell lines. Normalized luciferase activity was determined with the dual-luciferase reporter assay system (Promega) using the Luminoskan Ascent (Thermo Electron Corporation, MA) according to the supplier's recommendations. All experiments were analyzed independently three times.
###end p 19
###begin p 20
###xml 0 29 0 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Immunofluorescence Microscopy</italic>
###xml 1149 1150 1142 1143 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 418 422 <span type="species:ncbi:9925">goat</span>
###xml 459 464 <span type="species:ncbi:10090">mouse</span>
###xml 511 517 <span type="species:ncbi:9986">rabbit</span>
###xml 596 602 <span type="species:ncbi:9986">rabbit</span>
###xml 672 678 <span type="species:ncbi:9986">rabbit</span>
###xml 914 918 <span type="species:ncbi:9925">goat</span>
###xml 924 929 <span type="species:ncbi:10090">mouse</span>
###xml 976 980 <span type="species:ncbi:9925">goat</span>
###xml 986 992 <span type="species:ncbi:9986">rabbit</span>
Immunofluorescence Microscopy-Transfected NIH3T3 cells were plated into the Lab-tec chamber slide (Nalge Nunc International, NY). The next day, the cells were rinsed with phosphate-buffered saline and fixed in 4% paraformaldehyde for 15 min and cold methanol for 10 min. Nonspecific binding of the primary antibodies was reduced by first blocking the cells using a solution of phosphate-buffered saline with 5% normal goat serum for 60 min. Then anti-FLAG M2 mouse monoclonal (1:800, Sigma), anti-hemagglutinin rabbit polyclonal (Y-11, 1:200, Santa Cruz Biotechnology, Santa Cruz, CA), anti-SUFU rabbit monoclonal (C81H7, 1:200, Cell Signaling Technology), and anti-PTCH1 rabbit polyclonal (H-267, 1:100, Santa Cruz Biotechnology) in 0.3% Triton X-100/phosphate-buffered saline were added and incubated overnight at 4 degreesC. After the cells were washed, fluorescent-tagged secondary antibodies, Alexa Fluor 488-goat anti-mouse IgG (1:6000, Invitrogen), and Alexa Fluor 546-goat anti-rabbit IgG (1:6000, Invitrogen) were applied. Three phosphate-buffered saline washes (5 min) were also used after each treatment. The nuclei were stained with 5 mum DRAQ5 (Alexis Biochemicals, Lausen, Switzerland). Slides were mounted in FluorSave reagent (Carbiochem, Darmstadt, Germany). Fluorescence images were collected using a LSM510 (Carl Zeiss, Oberkochen, Germany) confocal laser-scanning microscope with a Plan APOCHROMAT x63/1.4 OilDIC objective lens.
###end p 20
###begin p 21
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Western Blotting</italic>
###xml 87 88 87 88 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 118 119 118 119 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 129 130 129 130 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 596 602 <span type="species:ncbi:9986">rabbit</span>
###xml 664 670 <span type="species:ncbi:9986">rabbit</span>
###xml 722 733 <span type="species:ncbi:3704">Horseradish</span>
###xml 761 767 <span type="species:ncbi:9986">rabbit</span>
Western Blotting-48 h after transfection, proteins were extracted by lysis buffer (50 mm Tris (pH 7.4), 1%. SDS, 250 mm NaCl, 2 mm dithiothreitol, 0.5% Nonidet P-40, 1% phosphatase inhibitor mixture 1 (Sigma), and 1% mammalian protease inhibitor mixture (Sigma)). After normalization based on protein concentration measured by the DC Protein assay kit (Bio-Rad), samples were run on a SDS-acrylamide gel. Thereafter, proteins were transferred onto Hybond-ECL nitrocellulose membrane (GE Healthcare). GLI1 isoforms or alpha/beta-tubulin as internal control were determined by the use of anti-GLI1 rabbit polyclonal (Cell Signaling Technology) or alpha/beta-tubulin rabbit polyclonal antibodies (Cell Signaling Technology). Horseradish peroxidase-conjugated anti-rabbit IgG (GE Healthcare) was used as the secondary antibody, followed by detection of these proteins with the Western Lightning Western blot Chemiluminescence Reagent Plus (PerkinElmer Life Sciences).
###end p 21
###begin p 22
###xml 0 39 0 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RNA Isolation and Reverse Transcription</italic>
###xml 281 282 279 280 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 302 303 300 301 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 334 336 332 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">18</sub>
###xml 498 499 487 488 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 98 101 <span type="species:ncbi:7460">Bee</span>
RNA Isolation and Reverse Transcription-Total RNA was isolated from cultured cells, using the RNA-Bee reagent (Tel-Test Inc., TX) or the RNeasy kit (Qiagen GmbH, Hilden, Germany) following the manufacturer's protocol. For reverse transcription, 5 mug of total RNA, 4 mul of a 2.5 mm dNTP mixture (2.5 mm each), and 0.5 ng of oligo(dT)18(A/C/G)(A/C/G/T) primer in a total volume of 12 mul were denatured at 65 degreesC for 5 min. After cooling the mixture on ice, 4 mul of 5x RT buffer, 2 mul of 0.1m dithiothreitol, and 1 mul of ribonuclease inhibitor (New England Biolabs) were added. Following incubation at 45 degreesC for 2 min, 1 mul of SuperScript II RT (Invitrogen) or water (negative control) was added. Then the mixture was incubated at 45 degreesC for 90 min. The reaction was stopped by heat inactivation at 75 degreesC for 15 min.
###end p 22
###begin p 23
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Real-time RT-PCR</italic>
###xml 101 119 101 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gli1, Ptch1, Ptch2</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sfrp</italic>
###xml 1096 1101 <span type="species:ncbi:9606">human</span>
###xml 1171 1176 <span type="species:ncbi:10090">mouse</span>
Real-time RT-PCR-Relative levels of the GLI1 variant RNAs or transcripts of the pathway target genes Gli1, Ptch1, Ptch2, and Sfrp were quantified by real-time RT-PCR using SYBR Green. Duplicate samples of each PCR mixture, each containing 4.7 mul of POWER SYBR Green PCR master mixture (Applied Biosystems), 0.3 mul of a 10 pmol/mul of primer mixture, 0.3-1.0 mul of cDNA, and water to a total volume of 10 mul were transferred into a 96-well plate on an ABI 7500 Fast Real Time PCR System (Applied Biosystems). The samples were initially incubated at 95 degreesC for 3 min, followed by 45 cycles with 95 degreesC for 15 s, 65 degreesC for 15 s, and 72 degreesC for 30 s. Dissociation curves were generated after each PCR run to ensure that a single, specific product was amplified. The results were analyzed with the comparative Cycle threshold (Ct) method. For normalization, we used the expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta-actin (ACTB), hypoxanthine phosphoribosyltransferase 1, ribosomal protein, large, P0 (RPLP0), and TATA box-binding protein for the human samples and Acidic ribosomal protein (Arp), Hprt1, and Gapdh for the mouse samples. From the results obtained the two housekeeping genes with the most scattered values were eliminated and then all data were normalized by the average Ct of the remaining housekeeping genes. Samples that were not reverse transcribed were used as negative controls. The PCR primers are shown in supplemental Table S1. The primer specificity was verified by BLAST searches and analysis of the PCR products by agarose gel electrophoresis followed by sequence determination.
###end p 23
###begin p 24
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Polysome Analysis</italic>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 140 141 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 213 214 212 213 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 354 355 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 591 592 584 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 442 445 <span type="species:ncbi:7460">Bee</span>
Polysome Analysis-GLI1 transcripts associated with polysomes were fractionated as described (31). In brief, cytoplasmic extracts from 1 x 107 RMS13 cells lysed in the presence of 50 mug/ml of cycloheximide or 25 mm EDTA were layered over a 15-40% sucrose (w/v) linear gradient and centrifuged in a SW55 Ti rotor (Beckman Coulter) for 120 min at 45,000 x g at 4 degreesC. Twenty fractions were collected and the RNA was isolated using the RNA-Bee reagent and LiCl precipitation. Transcript levels were measured by real-time RT-PCR as described above but with the use of random primer 6, 5'(dN6) (New England BioLabs). The percentage of individual transcripts in each gradient fraction was calculated from the Ct values. The isolated RNA from each fraction was also analyzed using denaturing 1.2% formaldehyde-agarose gel electrophoresis.
###end p 24
###begin p 25
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Statistical Analysis</italic>
Statistical Analysis-The statistical significance was calculated using the PRISM software (GraphPad Software, CA).
###end p 25
###begin title 26
RESULTS
###end title 26
###begin p 27
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Identification of Novel GLI1 Splice Variants</italic>
###xml 63 72 63 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico</italic>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 460 466 460 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 839 840 839 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 833 840 833 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 1152 1153 1140 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1146 1153 1134 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 228 233 <span type="species:ncbi:9606">human</span>
###xml 558 563 <span type="species:ncbi:9606">human</span>
###xml 568 573 <span type="species:ncbi:10090">mouse</span>
###xml 773 778 <span type="species:ncbi:9606">human</span>
###xml 1139 1144 <span type="species:ncbi:10090">mouse</span>
Identification of Novel GLI1 Splice Variants-We have performed in silico screening for novel splice variants in components of the HH signaling pathway, as described in a previous report (16). In a series of analyses, we found a human EST sequence (BX100365) of GLI1 with an uncharacterized splicing event. This sequence juxtaposed exon 1A directly to exon 4. Alternative splicing of GLI1 at the noncoding first exons 1 and 1A has already been reported by Wang et al. (25). Therefore, to analyze in detail the splicing pattern of GLI1, we performed RT-PCR on human and mouse cDNA panels with forward primers within exons 1 or 1A and a reverse primer within exon 4. The results showed that skipping of exons 2 and 3, with exon 1 spliced directly to exon 4, occurs in several human tissues, including lung, kidney, pancreas, and ovary (Fig. 1A). Moreover, the expression ratio of the two mRNAs was approximately1:1 and this was confirmed by real-time RT-PCR (data not shown). Additionally, similar results, with exon 1A and exon 4 spliced together, were also obtained (data not shown). Unexpectedly, these splicing events do not occur in the mouse (Fig. 1B, data not shown).
###end p 27
###begin p 28
###xml 195 196 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 189 196 185 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 286 288 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
The deduced protein structure of both exon 1 to exon 4 and exon 1A to exon 4 splice variants lacked 128 amino acids in the N-terminal end and thus the encoded variant is termed GLI1DeltaN (Fig. 1C). A SUFU binding sequence has already been reported to be present in the deleted region (26), and its absence is anticipated to influence the functional properties of the protein.
###end p 28
###begin p 29
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 9 54 9 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of novel GLI1 splice variants.</bold>
###xml 54 55 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 159 167 159 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E1&#8211;2&#8211;3&#8211;4</italic>
###xml 169 171 169 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FL</italic>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E1&#8211;4</italic>
###xml 225 226 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 268 269 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 329 333 325 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLI1</italic>
###xml 365 375 361 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Thicklines</italic>
###xml 677 678 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 728 734 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLI1FL</italic>
###xml 782 786 778 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLI1</italic>
###xml 791 792 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 795 806 787 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">White, gray</italic>
###xml 812 823 804 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black boxes</italic>
###xml 902 911 894 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold line</italic>
###xml 958 966 950 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Octagons</italic>
###xml 1000 1005 992 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">White</italic>
###xml 1010 1025 1002 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black triangles</italic>
###xml 1081 1084 1073 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NLS</italic>
###xml 1117 1120 1109 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NES</italic>
###xml 9 1122 9 1114 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30"><bold>Identification of novel GLI1 splice variants.</bold><italic>A</italic>, RT-PCR analysis using exon 1 forward and exon 4 reverse primers for GLI1 expression in human tissues. <italic>E1&#8211;2&#8211;3&#8211;4</italic> (<italic>FL</italic>) represents the full-length GLI1, whereas <italic>E1&#8211;4</italic> (&#916;<italic>N</italic>) the variant with skipped exons 2 and 3. <italic>B</italic>, comparison of the genomic structure between human andmouse<italic>GLI1</italic>in the region from exon 1 to 4. <italic>Thicklines</italic> show the novel splicing events identified in this report. The position for the initiator methionine codons for the full-length and the N-terminal deleted variants is indicated. Note the presence in the mouse of an additional first exon, E1B, which is inactivated in the human due to an Alu insertion. <italic>C</italic>, predicted protein domains for full-length GLI1 (<italic>GLI1FL</italic>) and the variant with the N-terminal deletion (<italic>GLI1</italic>&#916;<italic>N</italic>). <italic>White, gray</italic>, and <italic>black boxes</italic> indicate the Degron, SUFU binding, and zinc finger domains, respectively. The <italic>bold line</italic> indicates the additional SUFU binding region. <italic>Octagons</italic> represent the activation domain. <italic>White</italic> and <italic>black triangles</italic> show the position of the nuclear localization signals (<italic>NLS</italic>) and the nuclear export signal (<italic>NES</italic>).</p>
###xml 9 1122 9 1114 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30"><bold>Identification of novel GLI1 splice variants.</bold><italic>A</italic>, RT-PCR analysis using exon 1 forward and exon 4 reverse primers for GLI1 expression in human tissues. <italic>E1&#8211;2&#8211;3&#8211;4</italic> (<italic>FL</italic>) represents the full-length GLI1, whereas <italic>E1&#8211;4</italic> (&#916;<italic>N</italic>) the variant with skipped exons 2 and 3. <italic>B</italic>, comparison of the genomic structure between human andmouse<italic>GLI1</italic>in the region from exon 1 to 4. <italic>Thicklines</italic> show the novel splicing events identified in this report. The position for the initiator methionine codons for the full-length and the N-terminal deleted variants is indicated. Note the presence in the mouse of an additional first exon, E1B, which is inactivated in the human due to an Alu insertion. <italic>C</italic>, predicted protein domains for full-length GLI1 (<italic>GLI1FL</italic>) and the variant with the N-terminal deletion (<italic>GLI1</italic>&#916;<italic>N</italic>). <italic>White, gray</italic>, and <italic>black boxes</italic> indicate the Degron, SUFU binding, and zinc finger domains, respectively. The <italic>bold line</italic> indicates the additional SUFU binding region. <italic>Octagons</italic> represent the activation domain. <italic>White</italic> and <italic>black triangles</italic> show the position of the nuclear localization signals (<italic>NLS</italic>) and the nuclear export signal (<italic>NES</italic>).</p></caption>
###xml 1122 1122 1114 1114 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0250838450001"/>
###xml 0 1122 0 1114 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="30"><bold>Identification of novel GLI1 splice variants.</bold><italic>A</italic>, RT-PCR analysis using exon 1 forward and exon 4 reverse primers for GLI1 expression in human tissues. <italic>E1&#8211;2&#8211;3&#8211;4</italic> (<italic>FL</italic>) represents the full-length GLI1, whereas <italic>E1&#8211;4</italic> (&#916;<italic>N</italic>) the variant with skipped exons 2 and 3. <italic>B</italic>, comparison of the genomic structure between human andmouse<italic>GLI1</italic>in the region from exon 1 to 4. <italic>Thicklines</italic> show the novel splicing events identified in this report. The position for the initiator methionine codons for the full-length and the N-terminal deleted variants is indicated. Note the presence in the mouse of an additional first exon, E1B, which is inactivated in the human due to an Alu insertion. <italic>C</italic>, predicted protein domains for full-length GLI1 (<italic>GLI1FL</italic>) and the variant with the N-terminal deletion (<italic>GLI1</italic>&#916;<italic>N</italic>). <italic>White, gray</italic>, and <italic>black boxes</italic> indicate the Degron, SUFU binding, and zinc finger domains, respectively. The <italic>bold line</italic> indicates the additional SUFU binding region. <italic>Octagons</italic> represent the activation domain. <italic>White</italic> and <italic>black triangles</italic> show the position of the nuclear localization signals (<italic>NLS</italic>) and the nuclear export signal (<italic>NES</italic>).</p></caption><graphic xlink:href="zbc0250838450001"/></fig>
###xml 144 149 <span type="species:ncbi:9606">human</span>
###xml 315 320 <span type="species:ncbi:9606">human</span>
###xml 578 583 <span type="species:ncbi:10090">mouse</span>
###xml 646 651 <span type="species:ncbi:9606">human</span>
FIGURE 1.Identification of novel GLI1 splice variants.A, RT-PCR analysis using exon 1 forward and exon 4 reverse primers for GLI1 expression in human tissues. E1-2-3-4 (FL) represents the full-length GLI1, whereas E1-4 (DeltaN) the variant with skipped exons 2 and 3. B, comparison of the genomic structure between human andmouseGLI1in the region from exon 1 to 4. Thicklines show the novel splicing events identified in this report. The position for the initiator methionine codons for the full-length and the N-terminal deleted variants is indicated. Note the presence in the mouse of an additional first exon, E1B, which is inactivated in the human due to an Alu insertion. C, predicted protein domains for full-length GLI1 (GLI1FL) and the variant with the N-terminal deletion (GLI1DeltaN). White, gray, and black boxes indicate the Degron, SUFU binding, and zinc finger domains, respectively. The bold line indicates the additional SUFU binding region. Octagons represent the activation domain. White and black triangles show the position of the nuclear localization signals (NLS) and the nuclear export signal (NES).
###end p 29
###begin p 30
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of novel GLI1 splice variants.</bold>
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 150 158 150 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E1&#8211;2&#8211;3&#8211;4</italic>
###xml 160 162 160 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FL</italic>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E1&#8211;4</italic>
###xml 216 217 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 259 260 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 320 324 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLI1</italic>
###xml 356 366 352 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Thicklines</italic>
###xml 668 669 664 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 719 725 715 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLI1FL</italic>
###xml 773 777 769 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLI1</italic>
###xml 782 783 774 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 786 797 778 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">White, gray</italic>
###xml 803 814 795 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black boxes</italic>
###xml 893 902 885 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold line</italic>
###xml 949 957 941 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Octagons</italic>
###xml 991 996 983 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">White</italic>
###xml 1001 1016 993 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black triangles</italic>
###xml 1072 1075 1064 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NLS</italic>
###xml 1108 1111 1100 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NES</italic>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 306 311 <span type="species:ncbi:9606">human</span>
###xml 569 574 <span type="species:ncbi:10090">mouse</span>
###xml 637 642 <span type="species:ncbi:9606">human</span>
Identification of novel GLI1 splice variants.A, RT-PCR analysis using exon 1 forward and exon 4 reverse primers for GLI1 expression in human tissues. E1-2-3-4 (FL) represents the full-length GLI1, whereas E1-4 (DeltaN) the variant with skipped exons 2 and 3. B, comparison of the genomic structure between human andmouseGLI1in the region from exon 1 to 4. Thicklines show the novel splicing events identified in this report. The position for the initiator methionine codons for the full-length and the N-terminal deleted variants is indicated. Note the presence in the mouse of an additional first exon, E1B, which is inactivated in the human due to an Alu insertion. C, predicted protein domains for full-length GLI1 (GLI1FL) and the variant with the N-terminal deletion (GLI1DeltaN). White, gray, and black boxes indicate the Degron, SUFU binding, and zinc finger domains, respectively. The bold line indicates the additional SUFU binding region. Octagons represent the activation domain. White and black triangles show the position of the nuclear localization signals (NLS) and the nuclear export signal (NES).
###end p 30
###begin p 31
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLI1</italic>
###xml 9 41 5 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N Expression in Tumor Cell Lines</italic>
###xml 210 216 206 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 143 148 <span type="species:ncbi:9606">human</span>
###xml 1039 1044 <span type="species:ncbi:9606">human</span>
GLI1DeltaN Expression in Tumor Cell Lines-We also examined the GLI1 expression levels in nine human tumor cell lines and, as a control, in the human embryonic kidney cell line 293 (HEK293) by real-time RT-PCR (Fig. 2). Expression of both the full-length GLI1, GLI1FL, and GLI1DeltaN was observed in all cells analyzed, with the ratio of GLI1FL to GLI1DeltaN being about 9 times in HEK293 cells. Moreover, in the RMS13 and CCA cell lines that originate from rhabdomyosarcoma and in the Panc1 cell line originating from pancreatic tumor this expression ratio was less than 6 times. On the contrary, in the H23, H522, and A549 cell lines that originate from lung carcinoma the ratio reached and exceeded the value of 30. At this point it is difficult to determine whether these altered ratios of the GLI1 isoform expression may be relevant for HH signaling-dependent tumorigenesis. However, it is of interest to note that the relatively high GLI1 expression in the RMS13 cell line is also significantly higher than the levels observed in the human tissues analyzed before.
###end p 31
###begin p 32
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 65 9 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of GLI1FL and GLI1&#916;N in tumor cell lines.</bold>
###xml 177 178 169 170 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 183 184 175 176 <underline xmlns:xlink="http://www.w3.org/1999/xlink">t</underline>
###xml 381 393 365 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0, GAPDH</italic>
###xml 399 423 383 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATA box-binding protein</italic>
###xml 512 522 488 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 674 675 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 724 9 696 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><bold>Expression of GLI1FL and GLI1&#916;N in tumor cell lines.</bold> GLI1FL and GLI1&#916;N were quantified by real-time RT-PCR using SYBR Green. Data are presented as relative Ct (<underline>C</underline>ycle <underline>t</underline>hreshold, the cycle number at which the fluorescent emission reaches an arbitrary threshold) values (&#916;Ct), that is the Ct of GLI1FL or GLI1&#916;N minus the average Ct of the housekeeping genes <italic>RPLP0, GAPDH</italic>, and <italic>TATA box-binding protein</italic> in each sample. The expression ratio of GLI1FL to GLI1&#916;N is shown as FL/&#916;N. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant in all but the CCA cell line (<italic>p</italic> &lt; 0.001, analysis of variance, Bonferroni test).</p>
###xml 9 724 9 696 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33"><bold>Expression of GLI1FL and GLI1&#916;N in tumor cell lines.</bold> GLI1FL and GLI1&#916;N were quantified by real-time RT-PCR using SYBR Green. Data are presented as relative Ct (<underline>C</underline>ycle <underline>t</underline>hreshold, the cycle number at which the fluorescent emission reaches an arbitrary threshold) values (&#916;Ct), that is the Ct of GLI1FL or GLI1&#916;N minus the average Ct of the housekeeping genes <italic>RPLP0, GAPDH</italic>, and <italic>TATA box-binding protein</italic> in each sample. The expression ratio of GLI1FL to GLI1&#916;N is shown as FL/&#916;N. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant in all but the CCA cell line (<italic>p</italic> &lt; 0.001, analysis of variance, Bonferroni test).</p></caption>
###xml 724 724 696 696 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0250838450002"/>
###xml 0 724 0 696 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="33"><bold>Expression of GLI1FL and GLI1&#916;N in tumor cell lines.</bold> GLI1FL and GLI1&#916;N were quantified by real-time RT-PCR using SYBR Green. Data are presented as relative Ct (<underline>C</underline>ycle <underline>t</underline>hreshold, the cycle number at which the fluorescent emission reaches an arbitrary threshold) values (&#916;Ct), that is the Ct of GLI1FL or GLI1&#916;N minus the average Ct of the housekeeping genes <italic>RPLP0, GAPDH</italic>, and <italic>TATA box-binding protein</italic> in each sample. The expression ratio of GLI1FL to GLI1&#916;N is shown as FL/&#916;N. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant in all but the CCA cell line (<italic>p</italic> &lt; 0.001, analysis of variance, Bonferroni test).</p></caption><graphic xlink:href="zbc0250838450002"/></fig>
FIGURE 2.Expression of GLI1FL and GLI1DeltaN in tumor cell lines. GLI1FL and GLI1DeltaN were quantified by real-time RT-PCR using SYBR Green. Data are presented as relative Ct (Cycle threshold, the cycle number at which the fluorescent emission reaches an arbitrary threshold) values (DeltaCt), that is the Ct of GLI1FL or GLI1DeltaN minus the average Ct of the housekeeping genes RPLP0, GAPDH, and TATA box-binding protein in each sample. The expression ratio of GLI1FL to GLI1DeltaN is shown as FL/DeltaN. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant in all but the CCA cell line (p < 0.001, analysis of variance, Bonferroni test).
###end p 32
###begin p 33
###xml 0 56 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of GLI1FL and GLI1&#916;N in tumor cell lines.</bold>
###xml 168 169 160 161 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 174 175 166 167 <underline xmlns:xlink="http://www.w3.org/1999/xlink">t</underline>
###xml 372 384 356 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0, GAPDH</italic>
###xml 390 414 374 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TATA box-binding protein</italic>
###xml 503 513 479 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 665 666 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Expression of GLI1FL and GLI1DeltaN in tumor cell lines. GLI1FL and GLI1DeltaN were quantified by real-time RT-PCR using SYBR Green. Data are presented as relative Ct (Cycle threshold, the cycle number at which the fluorescent emission reaches an arbitrary threshold) values (DeltaCt), that is the Ct of GLI1FL or GLI1DeltaN minus the average Ct of the housekeeping genes RPLP0, GAPDH, and TATA box-binding protein in each sample. The expression ratio of GLI1FL to GLI1DeltaN is shown as FL/DeltaN. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant in all but the CCA cell line (p < 0.001, analysis of variance, Bonferroni test).
###end p 33
###begin p 34
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 67 9 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Up-regulation of GLI1 variants by HH signaling activation.</bold>
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 188 189 188 189 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 410 457 402 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0, hypoxanthine phosphoribosyltransferase 1</italic>
###xml 463 468 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 473 504 465 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH, TATA box-binding protein</italic>
###xml 510 514 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 634 644 626 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 777 778 769 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 826 9 818 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><bold>Up-regulation of GLI1 variants by HH signaling activation.</bold> hTERT-BJ1 human fibroblasts (<italic>A</italic>) or Daoy human medulloblastoma cells stably expressing EGFP (<italic>B</italic>) were incubated with 100 n<sc>m</sc> SAG followed by RNA isolation and reverse transcription. RT-PCR data using SYBR Green are presented as relative Ct values (&#916;Ct), which is the Ct of GLI1FL or GLI1&#916;N minus the average Ct of the housekeeping genes <italic>RPLP0, hypoxanthine phosphoribosyltransferase 1</italic>, and <italic>GAPDH</italic>, or <italic>GAPDH, TATA box-binding protein</italic>, and <italic>ACTB</italic> for the hTERT-BJ1 and EGFP-Daoy cells, respectively. The -fold increase of the GLI1 variants is shown as SAG/MtOH. The <italic>error bars</italic> indicate the standard deviation. The differences between the MtOH and SAG values were statistically significant in both cell lines (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test).</p>
###xml 9 826 9 818 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35"><bold>Up-regulation of GLI1 variants by HH signaling activation.</bold> hTERT-BJ1 human fibroblasts (<italic>A</italic>) or Daoy human medulloblastoma cells stably expressing EGFP (<italic>B</italic>) were incubated with 100 n<sc>m</sc> SAG followed by RNA isolation and reverse transcription. RT-PCR data using SYBR Green are presented as relative Ct values (&#916;Ct), which is the Ct of GLI1FL or GLI1&#916;N minus the average Ct of the housekeeping genes <italic>RPLP0, hypoxanthine phosphoribosyltransferase 1</italic>, and <italic>GAPDH</italic>, or <italic>GAPDH, TATA box-binding protein</italic>, and <italic>ACTB</italic> for the hTERT-BJ1 and EGFP-Daoy cells, respectively. The -fold increase of the GLI1 variants is shown as SAG/MtOH. The <italic>error bars</italic> indicate the standard deviation. The differences between the MtOH and SAG values were statistically significant in both cell lines (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test).</p></caption>
###xml 826 826 818 818 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0250838450003"/>
###xml 0 826 0 818 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="35"><bold>Up-regulation of GLI1 variants by HH signaling activation.</bold> hTERT-BJ1 human fibroblasts (<italic>A</italic>) or Daoy human medulloblastoma cells stably expressing EGFP (<italic>B</italic>) were incubated with 100 n<sc>m</sc> SAG followed by RNA isolation and reverse transcription. RT-PCR data using SYBR Green are presented as relative Ct values (&#916;Ct), which is the Ct of GLI1FL or GLI1&#916;N minus the average Ct of the housekeeping genes <italic>RPLP0, hypoxanthine phosphoribosyltransferase 1</italic>, and <italic>GAPDH</italic>, or <italic>GAPDH, TATA box-binding protein</italic>, and <italic>ACTB</italic> for the hTERT-BJ1 and EGFP-Daoy cells, respectively. The -fold increase of the GLI1 variants is shown as SAG/MtOH. The <italic>error bars</italic> indicate the standard deviation. The differences between the MtOH and SAG values were statistically significant in both cell lines (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test).</p></caption><graphic xlink:href="zbc0250838450003"/></fig>
###xml 78 83 <span type="species:ncbi:9606">human</span>
###xml 108 113 <span type="species:ncbi:9606">human</span>
FIGURE 3.Up-regulation of GLI1 variants by HH signaling activation. hTERT-BJ1 human fibroblasts (A) or Daoy human medulloblastoma cells stably expressing EGFP (B) were incubated with 100 nm SAG followed by RNA isolation and reverse transcription. RT-PCR data using SYBR Green are presented as relative Ct values (DeltaCt), which is the Ct of GLI1FL or GLI1DeltaN minus the average Ct of the housekeeping genes RPLP0, hypoxanthine phosphoribosyltransferase 1, and GAPDH, or GAPDH, TATA box-binding protein, and ACTB for the hTERT-BJ1 and EGFP-Daoy cells, respectively. The -fold increase of the GLI1 variants is shown as SAG/MtOH. The error bars indicate the standard deviation. The differences between the MtOH and SAG values were statistically significant in both cell lines (p < 0.01, analysis of variance, Bonferroni test).
###end p 34
###begin p 35
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Up-regulation of GLI1 variants by HH signaling activation.</bold>
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 179 180 179 180 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 401 448 393 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0, hypoxanthine phosphoribosyltransferase 1</italic>
###xml 454 459 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 464 495 456 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH, TATA box-binding protein</italic>
###xml 501 505 493 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 625 635 617 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 768 769 760 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 69 74 <span type="species:ncbi:9606">human</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
Up-regulation of GLI1 variants by HH signaling activation. hTERT-BJ1 human fibroblasts (A) or Daoy human medulloblastoma cells stably expressing EGFP (B) were incubated with 100 nm SAG followed by RNA isolation and reverse transcription. RT-PCR data using SYBR Green are presented as relative Ct values (DeltaCt), which is the Ct of GLI1FL or GLI1DeltaN minus the average Ct of the housekeeping genes RPLP0, hypoxanthine phosphoribosyltransferase 1, and GAPDH, or GAPDH, TATA box-binding protein, and ACTB for the hTERT-BJ1 and EGFP-Daoy cells, respectively. The -fold increase of the GLI1 variants is shown as SAG/MtOH. The error bars indicate the standard deviation. The differences between the MtOH and SAG values were statistically significant in both cell lines (p < 0.01, analysis of variance, Bonferroni test).
###end p 35
###begin p 36
###xml 0 44 0 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HH Signaling-dependent Transcription of GLI1</italic>
###xml 49 50 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 51 55 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GLI1</italic>
###xml 353 354 345 346 <underline xmlns:xlink="http://www.w3.org/1999/xlink">S</underline>
###xml 357 358 349 350 <underline xmlns:xlink="http://www.w3.org/1999/xlink">a</underline>
###xml 370 372 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref32">32</xref>
###xml 374 376 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref33">33</xref>
###xml 379 385 371 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 715 717 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref34">34</xref>
###xml 262 267 <span type="species:ncbi:9606">human</span>
HH Signaling-dependent Transcription of GLI1DeltaN-GLI1 is known to be a target gene of HH signaling and is frequently used as a marker of pathway activation. To study the HH signal dependence of GLI1DeltaN, we compared its mRNA levels to those of GLI1FL in the human BJ1 fibroblast and EGFP-Daoy medulloblastoma cell lines following treatment with the SMO agonist SAG (32, 33) (Fig. 3). Real-time RT-PCR analysis revealed that GLI1DeltaN is up-regulated by SAG to approximately the same extent as GLI1FL. Consequently, transcriptional activation is not altering the GLI1FL/GLI1DeltaN expression ratio in these cell lines, even though the phenomena of signaling regulation of splicing patterns are well documented (34). Thus, GLI1DeltaNis also a target of the HH pathway and therefore may be considered to represent a novel diagnostic marker for signaling activation.
###end p 36
###begin p 37
We also attempted to detect endogenous expression of the GLI1 isoforms by Western blotting. GLI1FL protein was detected in the RMS13 cell line but not in the SAG-treated EGFP-Daoy cells, in line with their relative mRNA levels. GLI1DeltaN could not be detected even in the RMS13 cell lines, as its mRNA levels are comparable with the ones of GLI1FL in the SAG-treated EGFP-Daoy cells (supplemental Fig. S1).
###end p 37
###begin p 38
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 9 50 9 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Association of GLI1&#916;N with polysomes.</bold>
###xml 83 84 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 144 145 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 156 157 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 272 275 268 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 296 302 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 337 351 333 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">filled squares</italic>
###xml 367 380 359 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">empty circles</italic>
###xml 451 463 443 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panels</italic>
###xml 638 650 630 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panels</italic>
###xml 9 652 9 644 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39"><bold>Association of GLI1&#916;N with polysomes.</bold> Cytoplasmic extracts from 1 &#215; 10<sup>7</sup> RMS13 cells lysed in the presence of either cycloheximide (<italic>A</italic>) or EDTA (<italic>B</italic>) were subjected to a 15&#8211;40% sucrose density gradient centrifugation. Twenty fractions were collected (fraction 1, <italic>top</italic>/light; fraction 20, <italic>bottom</italic>/heavy). The percentage of GLI1FL (<italic>filled squares</italic>) or GLI1&#916;N(<italic>empty circles</italic>) transcripts per fraction, determined by real-time RT-PCR, are shown (<italic>lower panels</italic>). The isolated RNAs from the individual fractions were also subjected to denaturing 1.2% formaldehyde-agarose gel electrophoresis followed by staining with ethidium bromide (<italic>upper panels</italic>).</p>
###xml 9 652 9 644 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39"><bold>Association of GLI1&#916;N with polysomes.</bold> Cytoplasmic extracts from 1 &#215; 10<sup>7</sup> RMS13 cells lysed in the presence of either cycloheximide (<italic>A</italic>) or EDTA (<italic>B</italic>) were subjected to a 15&#8211;40% sucrose density gradient centrifugation. Twenty fractions were collected (fraction 1, <italic>top</italic>/light; fraction 20, <italic>bottom</italic>/heavy). The percentage of GLI1FL (<italic>filled squares</italic>) or GLI1&#916;N(<italic>empty circles</italic>) transcripts per fraction, determined by real-time RT-PCR, are shown (<italic>lower panels</italic>). The isolated RNAs from the individual fractions were also subjected to denaturing 1.2% formaldehyde-agarose gel electrophoresis followed by staining with ethidium bromide (<italic>upper panels</italic>).</p></caption>
###xml 652 652 644 644 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0250838450004"/>
###xml 0 652 0 644 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="39"><bold>Association of GLI1&#916;N with polysomes.</bold> Cytoplasmic extracts from 1 &#215; 10<sup>7</sup> RMS13 cells lysed in the presence of either cycloheximide (<italic>A</italic>) or EDTA (<italic>B</italic>) were subjected to a 15&#8211;40% sucrose density gradient centrifugation. Twenty fractions were collected (fraction 1, <italic>top</italic>/light; fraction 20, <italic>bottom</italic>/heavy). The percentage of GLI1FL (<italic>filled squares</italic>) or GLI1&#916;N(<italic>empty circles</italic>) transcripts per fraction, determined by real-time RT-PCR, are shown (<italic>lower panels</italic>). The isolated RNAs from the individual fractions were also subjected to denaturing 1.2% formaldehyde-agarose gel electrophoresis followed by staining with ethidium bromide (<italic>upper panels</italic>).</p></caption><graphic xlink:href="zbc0250838450004"/></fig>
FIGURE 4.Association of GLI1DeltaN with polysomes. Cytoplasmic extracts from 1 x 107 RMS13 cells lysed in the presence of either cycloheximide (A) or EDTA (B) were subjected to a 15-40% sucrose density gradient centrifugation. Twenty fractions were collected (fraction 1, top/light; fraction 20, bottom/heavy). The percentage of GLI1FL (filled squares) or GLI1DeltaN(empty circles) transcripts per fraction, determined by real-time RT-PCR, are shown (lower panels). The isolated RNAs from the individual fractions were also subjected to denaturing 1.2% formaldehyde-agarose gel electrophoresis followed by staining with ethidium bromide (upper panels).
###end p 38
###begin p 39
###xml 0 41 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Association of GLI1&#916;N with polysomes.</bold>
###xml 74 75 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 135 136 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 147 148 143 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 263 266 259 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 287 293 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 328 342 324 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">filled squares</italic>
###xml 358 371 350 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">empty circles</italic>
###xml 442 454 434 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower panels</italic>
###xml 629 641 621 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper panels</italic>
Association of GLI1DeltaN with polysomes. Cytoplasmic extracts from 1 x 107 RMS13 cells lysed in the presence of either cycloheximide (A) or EDTA (B) were subjected to a 15-40% sucrose density gradient centrifugation. Twenty fractions were collected (fraction 1, top/light; fraction 20, bottom/heavy). The percentage of GLI1FL (filled squares) or GLI1DeltaN(empty circles) transcripts per fraction, determined by real-time RT-PCR, are shown (lower panels). The isolated RNAs from the individual fractions were also subjected to denaturing 1.2% formaldehyde-agarose gel electrophoresis followed by staining with ethidium bromide (upper panels).
###end p 39
###begin p 40
###xml 0 24 0 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Polysome Profile of GLI1</italic>
###xml 29 30 25 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 493 495 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 620 621 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 614 621 598 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 692 694 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 819 820 799 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 813 820 793 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4<italic>B</italic></xref>
Polysome Profile of GLI1DeltaN-The difficulty of detecting the GLI1DeltaN protein by Western blotting prompted us to examine whether the GLI1DeltaN mRNA is associated with polyribosomes, as this would imply translatability. To this end cytoplasmic extracts of RMS13 cells were subjected to sucrose density gradient centrifugation to separate the polysomal from the ribosome-free mRNA fractions. In the presence of cycloheximide, which prevents ribosome dissociation from the translating mRNA (31), the GLI1DeltaN mRNA was mostly found in the heavier fractions containing the polyribosomes, as was the GLI1FL mRNA (Fig. 4A). In the presence of EDTA, which disrupts ribosome-mRNA associations (31), there was a shift of both the GLI1DeltaN and GLI1FL mRNAs toward lighter fractions that contain ribosome-free mRNA (Fig. 4B). Thus, the polysome profiles of the GLI1DeltaN and GLI1FL mRNAs are quite similar, and therefore it is very likely that the GLI1DeltaN mRNA is also translated, even though its low expression prohibits detection of the protein by Western blotting.
###end p 40
###begin p 41
###xml 0 36 0 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Biochemical Characterization of GLI1</italic>
###xml 41 42 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 369 370 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 363 370 351 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 605 606 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 611 612 595 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 597 612 581 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, <italic>B</italic> and <italic>C</italic></xref>
Biochemical Characterization of GLI1DeltaN-To elucidate the functional role of GLI1DeltaN, this as well as GLI1FL were cloned into the three mammalian expression vectors, pCMV5, pBABEpuro, and pEGFP. Although there were differences in protein expression depending on the vector used, there was a similar expression of both GLI1FL and GLI1DeltaN with each vector (Fig. 5A). On the other hand, the transcriptional activity, as determined by the 12xGLIBS-luc reporter, was higher for GLI1FL than GLI1DeltaN in the FLAG-tagged pCMV5 and pBABEpuro constructs, regardless of the transfected cell lines (Fig. 5, B and C, and supplemental Fig. S2). However, in the pEGFP constructs the activity of GLI1FL and GLI1DeltaN was comparable, possibly indicating that the bulky EGFP tag at the C terminus may interfere with the GLI1 activity. It therefore appears that in the cellular assays used, GLI1DeltaN has no increased transcriptional capacity relative to GLI1FL, even though it lacks one binding domain for the negative regulator of the pathway, SUFU.
###end p 41
###begin p 42
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref35">35</xref>
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref36">36</xref>
###xml 85 86 85 86 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 89 92 89 92 <underline xmlns:xlink="http://www.w3.org/1999/xlink">ant</underline>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref37">37</xref>
###xml 362 363 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 356 363 348 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>D</italic></xref>
###xml 522 523 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 516 523 504 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5<italic>E</italic></xref>
###xml 676 677 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn6">6</xref>
Inhibition of GLI1 activity by SUFU (26, 35), PTCH1 (16, 36), and the small molecule Gli antagonists, GANT58 and GANT61 (37), has already been reported. Therefore we analyzed the sensitivity of GLI1DeltaN to these inhibitors. As expected, GLI1DeltaN, which lacks the N-terminal SUFU binding domain, had a weaker repression by SUFU in comparison to GLI1FL (Fig. 5D). On the other hand, PTCH1 could inhibit GLI1DeltaN activity to the same extent as GLI1FL, and this was not dependent on the PTCH1 splice variant used (Fig. 5E and supplemental Fig. S3). Furthermore, we could not measure a significant difference in repression by GANT58 and GANT61, between GLI1DeltaN and GLI1FL.6
###end p 42
###begin p 43
###xml 0 32 0 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Subcellular Localization of GLI1</italic>
###xml 37 38 33 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 48 53 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 56 58 52 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 385 386 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 379 386 371 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 718 719 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 712 719 700 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>B</italic></xref>
Subcellular Localization of GLI1DeltaN-Kogerman et al. (29) showed that the subcellular localization of GLI1 is regulated by SUFU, resulting in sequestration of GLI1 to the cytoplasm. To clarify the effect of the lack of the N-terminal region and the SUFU binding domain of GLI1 on localization, we transfected the FLAG-tagged GLI1DeltaN and GLI1FL constructs into NIH3T3 cells (Fig. 6A). GLI1FL localized in the nucleus, but GLI1DeltaN had a broader signal in both the nucleus and cytoplasm with a punctiform pattern, in line with its reduced transcriptional capacity. To further examine the relation between GLI1 localization and activity, we co-transfected the GLI1 constructs and SUFU into the NIH3T3 cells (Fig. 6B). Both GLI1FL and GLI1DeltaN accumulated in the cytoplasm, indicating a dramatic influence of SUFU on GLI1FL localization, which parallels its strong inhibitory effects on the transcriptional activity. PTCH1 co-transfection also resulted in cytoplasmic accumulation of both GLI1 isoforms, in line with the PTCH1 negative influence on GLI1 activity (supplemental Fig. S4).
###end p 43
###begin p 44
###xml 128 129 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 122 129 118 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2<italic>B</italic></xref>
Interestingly, the GLI1FL and GLI1DeltaN constructs with the EGFP tags, which have a comparable transcriptional activity (Fig. 2B), also have a comparable localization pattern, with presence mainly in the cytoplasm (supplemental Fig. S5). Thus, inclusion of the bulky EGFP tag apparently alters the nuclear-only distribution of the GLI1FL isoform. Consequently, the GLI1 transcriptional activity is positively influenced by nuclear accumulation, with SUFU having a strong capacity for cytoplasmic sequestration of the GLI1FL isoform.
###end p 44
###begin p 45
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 9 52 9 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Biochemical characterization of GLI1&#916;N.</bold>
###xml 52 53 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 334 335 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 423 433 404 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bars</italic>
###xml 445 455 426 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 579 589 560 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 781 782 758 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 832 833 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1038 1048 1015 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 1171 1172 1144 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1221 1222 1194 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1527 1537 1500 1510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 1714 1715 1683 1684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1764 1765 1733 1734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 2083 2093 2052 2062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 9 2259 9 2224 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46"><bold>Biochemical characterization of GLI1&#916;N.</bold><italic>A</italic>, protein expression following transfection of FLAG-tagged pCMV5 and pBABEpuro or EGFP-tagged pEGFP constructs of GLI1&#916;N and GLI1FL into HEK293 cells. Western blotting was performed using an anti-GLI1 antibody. &#945;,&#946;-Tubulin expression is also shown as a loading control. <italic>B</italic>, the luciferase activity of the GLI1&#916;N and GLI1FL constructs in HEK293 cells. Ten (<italic>white bars</italic>) or 50 ng (<italic>black bars</italic>) of the GLI1 expression constructs were transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant with the pBABEpuro constructs and with 10 ng of the pCMV5 constructs (<italic>p</italic> &lt; 0.001, analysis of variance, Bonferroni test). <italic>C</italic>, dose-dependent GLI1 activity in NIH3T3 cells. Different amounts of FLAG-tagged pCMV5 GLI1 expression constructs were co-transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test). <italic>D</italic>, inhibition of GLI1 activity by SUFU. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 1&#8211;100 ng of the SUFU expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without SUFU. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant only when 10 or 25 ng of the SUFU construct were used (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test). <italic>E</italic>, inhibition of GLI1 activity by PTCH1-1B. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 20&#8211;200 ng of the PTCH1-1B expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without PTCH1-1B. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were not statistically significant (analysis of variance, Bonferroni test).</p>
###xml 9 2259 9 2224 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46"><bold>Biochemical characterization of GLI1&#916;N.</bold><italic>A</italic>, protein expression following transfection of FLAG-tagged pCMV5 and pBABEpuro or EGFP-tagged pEGFP constructs of GLI1&#916;N and GLI1FL into HEK293 cells. Western blotting was performed using an anti-GLI1 antibody. &#945;,&#946;-Tubulin expression is also shown as a loading control. <italic>B</italic>, the luciferase activity of the GLI1&#916;N and GLI1FL constructs in HEK293 cells. Ten (<italic>white bars</italic>) or 50 ng (<italic>black bars</italic>) of the GLI1 expression constructs were transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant with the pBABEpuro constructs and with 10 ng of the pCMV5 constructs (<italic>p</italic> &lt; 0.001, analysis of variance, Bonferroni test). <italic>C</italic>, dose-dependent GLI1 activity in NIH3T3 cells. Different amounts of FLAG-tagged pCMV5 GLI1 expression constructs were co-transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test). <italic>D</italic>, inhibition of GLI1 activity by SUFU. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 1&#8211;100 ng of the SUFU expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without SUFU. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant only when 10 or 25 ng of the SUFU construct were used (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test). <italic>E</italic>, inhibition of GLI1 activity by PTCH1-1B. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 20&#8211;200 ng of the PTCH1-1B expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without PTCH1-1B. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were not statistically significant (analysis of variance, Bonferroni test).</p></caption>
###xml 2259 2259 2224 2224 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0250838450005"/>
###xml 0 2259 0 2224 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="46"><bold>Biochemical characterization of GLI1&#916;N.</bold><italic>A</italic>, protein expression following transfection of FLAG-tagged pCMV5 and pBABEpuro or EGFP-tagged pEGFP constructs of GLI1&#916;N and GLI1FL into HEK293 cells. Western blotting was performed using an anti-GLI1 antibody. &#945;,&#946;-Tubulin expression is also shown as a loading control. <italic>B</italic>, the luciferase activity of the GLI1&#916;N and GLI1FL constructs in HEK293 cells. Ten (<italic>white bars</italic>) or 50 ng (<italic>black bars</italic>) of the GLI1 expression constructs were transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant with the pBABEpuro constructs and with 10 ng of the pCMV5 constructs (<italic>p</italic> &lt; 0.001, analysis of variance, Bonferroni test). <italic>C</italic>, dose-dependent GLI1 activity in NIH3T3 cells. Different amounts of FLAG-tagged pCMV5 GLI1 expression constructs were co-transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test). <italic>D</italic>, inhibition of GLI1 activity by SUFU. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 1&#8211;100 ng of the SUFU expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without SUFU. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant only when 10 or 25 ng of the SUFU construct were used (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test). <italic>E</italic>, inhibition of GLI1 activity by PTCH1-1B. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 20&#8211;200 ng of the PTCH1-1B expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without PTCH1-1B. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were not statistically significant (analysis of variance, Bonferroni test).</p></caption><graphic xlink:href="zbc0250838450005"/></fig>
FIGURE 5.Biochemical characterization of GLI1DeltaN.A, protein expression following transfection of FLAG-tagged pCMV5 and pBABEpuro or EGFP-tagged pEGFP constructs of GLI1DeltaN and GLI1FL into HEK293 cells. Western blotting was performed using an anti-GLI1 antibody. alpha,beta-Tubulin expression is also shown as a loading control. B, the luciferase activity of the GLI1DeltaN and GLI1FL constructs in HEK293 cells. Ten (white bars) or 50 ng (black bars) of the GLI1 expression constructs were transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant with the pBABEpuro constructs and with 10 ng of the pCMV5 constructs (p < 0.001, analysis of variance, Bonferroni test). C, dose-dependent GLI1 activity in NIH3T3 cells. Different amounts of FLAG-tagged pCMV5 GLI1 expression constructs were co-transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant (p < 0.01, analysis of variance, Bonferroni test). D, inhibition of GLI1 activity by SUFU. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 1-100 ng of the SUFU expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without SUFU. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant only when 10 or 25 ng of the SUFU construct were used (p < 0.01, analysis of variance, Bonferroni test). E, inhibition of GLI1 activity by PTCH1-1B. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 20-200 ng of the PTCH1-1B expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without PTCH1-1B. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were not statistically significant (analysis of variance, Bonferroni test).
###end p 45
###begin p 46
###xml 0 43 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Biochemical characterization of GLI1&#916;N.</bold>
###xml 43 44 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 325 326 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 414 424 395 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white bars</italic>
###xml 436 446 417 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black bars</italic>
###xml 570 580 551 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 772 773 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 823 824 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1029 1039 1006 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 1162 1163 1135 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1212 1213 1185 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1518 1528 1491 1501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 1705 1706 1674 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1755 1756 1724 1725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 2074 2084 2043 2053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
Biochemical characterization of GLI1DeltaN.A, protein expression following transfection of FLAG-tagged pCMV5 and pBABEpuro or EGFP-tagged pEGFP constructs of GLI1DeltaN and GLI1FL into HEK293 cells. Western blotting was performed using an anti-GLI1 antibody. alpha,beta-Tubulin expression is also shown as a loading control. B, the luciferase activity of the GLI1DeltaN and GLI1FL constructs in HEK293 cells. Ten (white bars) or 50 ng (black bars) of the GLI1 expression constructs were transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant with the pBABEpuro constructs and with 10 ng of the pCMV5 constructs (p < 0.001, analysis of variance, Bonferroni test). C, dose-dependent GLI1 activity in NIH3T3 cells. Different amounts of FLAG-tagged pCMV5 GLI1 expression constructs were co-transfected with 200 ng of 12xGLIBS-luc and 50 ng of pRL-SV reporter plasmids. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant (p < 0.01, analysis of variance, Bonferroni test). D, inhibition of GLI1 activity by SUFU. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 1-100 ng of the SUFU expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without SUFU. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant only when 10 or 25 ng of the SUFU construct were used (p < 0.01, analysis of variance, Bonferroni test). E, inhibition of GLI1 activity by PTCH1-1B. NIH3T3 cells were co-transfected with 50 ng of the FLAG-tagged pCMV5 GLI1 constructs and 20-200 ng of the PTCH1-1B expression construct, and the luciferase activity of the 12xGLIBS-luc reporter was measured. The control values represent GLI1 activities without PTCH1-1B. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were not statistically significant (analysis of variance, Bonferroni test).
###end p 46
###begin p 47
###xml 0 18 0 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Regulation of GLI1</italic>
###xml 23 100 19 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N by the Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1 (Dyrk1)</italic>
###xml 105 110 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 113 115 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 379 381 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 510 516 498 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7</xref>
###xml 1041 1047 1025 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 1049 1051 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
Regulation of GLI1DeltaN by the Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1 (Dyrk1)-Mao et al. (27) showed that GLI1 localization and activity are also regulated by the Dyrk1 kinase. To examine the role of Dyrk1 on GLI1DeltaN, we first co-transfected the FLAG-tagged pCMV5 GLI1 constructs with either wild type Dyrk1 (Dyrk1WT) or a kinase-null mutant (Dyrk1KR) (27) in NIH3T3 cells, and compared the GLI1 activity. Surprisingly, Dyrk1WT enhanced the activity of GLI1FL, but not of GLI1DeltaN (Fig. 7). Moreover, Dyrk1KR repressed GLI1DeltaN, but not GLI1FL. This implies that the two isoforms of GLI1 respond differently to Dyrk1 kinase signaling. When the subcellular localization of the GLI1 isoforms was examined in the presence or absence of Dyrk1WT or Dyrk1KR, no major changes were observed (supplemental Fig. S6). However, when instead of the FLAG-tagged the EGFP-tagged GLI1FL construct was used, which shows a mainly cytoplasmic localization, Dyrk1WT co-transfection resulted in a nucleus shift, as observed by Mao et al. (27) (supplemental Fig. S7). These results clearly indicate that the Dyrk1 kinase differentially regulates the activity of GLI1FL and GLI1DeltaN, but without significant changes in subcellular localization that are detected at the resolution of the immunofluorescence assay used.
###end p 47
###begin p 48
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 9 48 9 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Subcellular localization of GLI1&#916;N.</bold>
###xml 97 109 89 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green signal</italic>
###xml 157 168 149 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue signal</italic>
###xml 320 321 312 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 436 450 428 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red scale bars</italic>
###xml 469 470 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 590 600 577 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red signal</italic>
###xml 665 679 652 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red scale bars</italic>
###xml 9 697 9 683 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49"><bold>Subcellular localization of GLI1&#916;N.</bold> The FLAG-tagged GLI1&#916;N and GLI1FL isoforms (<italic>green signal</italic>) and the nuclei stained with the marker DRAQ5 (<italic>blue signal</italic>) were visualized by immunofluorescence microscopy. The majority of the green signal positive cells showed a similar distribution pattern in each case. <italic>A</italic>, differential localization of the GLI1 variants. NIH3T3 cells were transfected with 100 ng of the constructs. The <italic>red scale bars</italic> represent 20 &#956;m. <italic>B</italic>, cytoplasmic sequestration of GLI1&#916;N and GLI1FL by SUFU. NIH3T3 cells were co-transfected with 200 ng of the SUFU (<italic>red signal</italic>) and 100 ng of the GLI1 constructs or a pCMV5 empty vector. The <italic>red scale bars</italic> represent 20 &#956;m.</p>
###xml 9 697 9 683 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49"><bold>Subcellular localization of GLI1&#916;N.</bold> The FLAG-tagged GLI1&#916;N and GLI1FL isoforms (<italic>green signal</italic>) and the nuclei stained with the marker DRAQ5 (<italic>blue signal</italic>) were visualized by immunofluorescence microscopy. The majority of the green signal positive cells showed a similar distribution pattern in each case. <italic>A</italic>, differential localization of the GLI1 variants. NIH3T3 cells were transfected with 100 ng of the constructs. The <italic>red scale bars</italic> represent 20 &#956;m. <italic>B</italic>, cytoplasmic sequestration of GLI1&#916;N and GLI1FL by SUFU. NIH3T3 cells were co-transfected with 200 ng of the SUFU (<italic>red signal</italic>) and 100 ng of the GLI1 constructs or a pCMV5 empty vector. The <italic>red scale bars</italic> represent 20 &#956;m.</p></caption>
###xml 697 697 683 683 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0250838450006"/>
###xml 0 697 0 683 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="49"><bold>Subcellular localization of GLI1&#916;N.</bold> The FLAG-tagged GLI1&#916;N and GLI1FL isoforms (<italic>green signal</italic>) and the nuclei stained with the marker DRAQ5 (<italic>blue signal</italic>) were visualized by immunofluorescence microscopy. The majority of the green signal positive cells showed a similar distribution pattern in each case. <italic>A</italic>, differential localization of the GLI1 variants. NIH3T3 cells were transfected with 100 ng of the constructs. The <italic>red scale bars</italic> represent 20 &#956;m. <italic>B</italic>, cytoplasmic sequestration of GLI1&#916;N and GLI1FL by SUFU. NIH3T3 cells were co-transfected with 200 ng of the SUFU (<italic>red signal</italic>) and 100 ng of the GLI1 constructs or a pCMV5 empty vector. The <italic>red scale bars</italic> represent 20 &#956;m.</p></caption><graphic xlink:href="zbc0250838450006"/></fig>
FIGURE 6.Subcellular localization of GLI1DeltaN. The FLAG-tagged GLI1DeltaN and GLI1FL isoforms (green signal) and the nuclei stained with the marker DRAQ5 (blue signal) were visualized by immunofluorescence microscopy. The majority of the green signal positive cells showed a similar distribution pattern in each case. A, differential localization of the GLI1 variants. NIH3T3 cells were transfected with 100 ng of the constructs. The red scale bars represent 20 mum. B, cytoplasmic sequestration of GLI1DeltaN and GLI1FL by SUFU. NIH3T3 cells were co-transfected with 200 ng of the SUFU (red signal) and 100 ng of the GLI1 constructs or a pCMV5 empty vector. The red scale bars represent 20 mum.
###end p 48
###begin p 49
###xml 0 39 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Subcellular localization of GLI1&#916;N.</bold>
###xml 88 100 80 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green signal</italic>
###xml 148 159 140 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue signal</italic>
###xml 311 312 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 427 441 419 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red scale bars</italic>
###xml 460 461 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 581 591 568 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red signal</italic>
###xml 656 670 643 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red scale bars</italic>
Subcellular localization of GLI1DeltaN. The FLAG-tagged GLI1DeltaN and GLI1FL isoforms (green signal) and the nuclei stained with the marker DRAQ5 (blue signal) were visualized by immunofluorescence microscopy. The majority of the green signal positive cells showed a similar distribution pattern in each case. A, differential localization of the GLI1 variants. NIH3T3 cells were transfected with 100 ng of the constructs. The red scale bars represent 20 mum. B, cytoplasmic sequestration of GLI1DeltaN and GLI1FL by SUFU. NIH3T3 cells were co-transfected with 200 ng of the SUFU (red signal) and 100 ng of the GLI1 constructs or a pCMV5 empty vector. The red scale bars represent 20 mum.
###end p 49
###begin p 50
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 7.</label>
###xml 9 43 9 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Regulation of GLI1&#916;N by Dyrk1.</bold>
###xml 290 300 286 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 423 424 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 473 9 465 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51"><bold>Regulation of GLI1&#916;N by Dyrk1.</bold> Fifty ng of the FLAG-tagged pCMV5 GLI1 constructs were co-transfected with 100 ng of kinase-null (Dyrk1KR) or wild type Dyrk1 (Dyrk1WT) expression constructs in NIH3T3 cells. The luciferase activity of the 12xGLIBS-luc reporter was measured. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant (<italic>p</italic> &lt; 0.001, analysis of variance, Bonferroni test).</p>
###xml 9 473 9 465 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51"><bold>Regulation of GLI1&#916;N by Dyrk1.</bold> Fifty ng of the FLAG-tagged pCMV5 GLI1 constructs were co-transfected with 100 ng of kinase-null (Dyrk1KR) or wild type Dyrk1 (Dyrk1WT) expression constructs in NIH3T3 cells. The luciferase activity of the 12xGLIBS-luc reporter was measured. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant (<italic>p</italic> &lt; 0.001, analysis of variance, Bonferroni test).</p></caption>
###xml 473 473 465 465 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0250838450007"/>
###xml 0 473 0 465 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig7"><label>FIGURE 7.</label><caption><p textid="51"><bold>Regulation of GLI1&#916;N by Dyrk1.</bold> Fifty ng of the FLAG-tagged pCMV5 GLI1 constructs were co-transfected with 100 ng of kinase-null (Dyrk1KR) or wild type Dyrk1 (Dyrk1WT) expression constructs in NIH3T3 cells. The luciferase activity of the 12xGLIBS-luc reporter was measured. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant (<italic>p</italic> &lt; 0.001, analysis of variance, Bonferroni test).</p></caption><graphic xlink:href="zbc0250838450007"/></fig>
FIGURE 7.Regulation of GLI1DeltaN by Dyrk1. Fifty ng of the FLAG-tagged pCMV5 GLI1 constructs were co-transfected with 100 ng of kinase-null (Dyrk1KR) or wild type Dyrk1 (Dyrk1WT) expression constructs in NIH3T3 cells. The luciferase activity of the 12xGLIBS-luc reporter was measured. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant (p < 0.001, analysis of variance, Bonferroni test).
###end p 50
###begin p 51
###xml 0 34 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Regulation of GLI1&#916;N by Dyrk1.</bold>
###xml 281 291 277 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 414 415 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Regulation of GLI1DeltaN by Dyrk1. Fifty ng of the FLAG-tagged pCMV5 GLI1 constructs were co-transfected with 100 ng of kinase-null (Dyrk1KR) or wild type Dyrk1 (Dyrk1WT) expression constructs in NIH3T3 cells. The luciferase activity of the 12xGLIBS-luc reporter was measured. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant (p < 0.001, analysis of variance, Bonferroni test).
###end p 51
###begin p 52
###xml 0 32 0 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Transcriptional Activity of GLI1</italic>
###xml 37 54 33 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N on Target Genes</italic>
###xml 194 213 190 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTCH1, PTCH2, IL1R2</italic>
###xml 219 223 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP</italic>
###xml 231 233 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 235 237 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 239 241 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref38">38</xref>
###xml 243 245 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref39">39</xref>
###xml 455 460 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch1</italic>
###xml 470 475 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTCH2</italic>
###xml 481 486 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R2</italic>
###xml 555 558 547 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;C</italic>
###xml 547 558 539 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8, <italic>A&#8211;C</italic></xref>
###xml 894 905 878 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gli1, Ptch1</italic>
###xml 911 916 895 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch2</italic>
###xml 940 944 924 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sfrp</italic>
###xml 1067 1068 1047 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1061 1068 1041 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8<italic>D</italic></xref>
###xml 1198 1202 1174 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gli1</italic>
###xml 1238 1239 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1232 1239 1208 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8<italic>E</italic></xref>
Transcriptional Activity of GLI1DeltaN on Target Genes-GLI1 is a transcription factor, which acts as the terminal effector of HH signaling. Targets of the pathway include the well characterized PTCH1, PTCH2, IL1R2, and SFRP genes (13, 30, 38, 39). To evaluate the role of the GLI1 isoforms as effective transducers of HH signaling, we measured the transcriptional activity of GLI1DeltaN and GLI1FL, not only with the 12xGLI1BS-luc reporter, but also with Ptch1 exon 1B, PTCH2, and IL1R2 promoter constructs cloned upstream of the luciferase gene (Fig. 8, A-C). GLI1DeltaN up-regulated all reporter constructs in NIH3T3 cells, but the activation was not as strong as that seen with GLI1FL. To examine this observation in a more natural context, the transcriptional response of endogenous genes was analyzed by real-time RT-PCR. Overexpression of GLI1FL or GLI1DeltaNin NIH3T3 cells up-regulated Gli1, Ptch1, and Ptch2 and to a lesser extent Sfrp transcription, with the GLI1FL effects being more pronounced than GLI1DeltaN, as seen with the reporter constructs (Fig. 8D). However, in C3H10T1/2 cells, there was an increase in the relative activation capacity of GLI1DeltaN, which in the case of the Gli1 gene was higher than GLI1FL (Fig. 8E). These results suggest that GLI1FL and GLI1DeltaN may up-regulate the same target genes but their activities are independently regulated.
###end p 52
###begin p 53
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 8.</label>
###xml 9 64 9 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Transcriptional activity of GLI1&#916;N on target genes.</bold>
###xml 128 133 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch1</italic>
###xml 142 143 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 146 151 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTCH2</italic>
###xml 157 158 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 164 169 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R2</italic>
###xml 175 176 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 274 284 270 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 454 462 446 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panels B</italic>
###xml 467 468 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 470 471 462 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 520 521 512 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 526 527 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 943 944 927 928 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1022 1040 1006 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch1, Ptch2, Gli1</italic>
###xml 1046 1050 1030 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sfrp</italic>
###xml 1234 1237 1214 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arp</italic>
###xml 1243 1253 1223 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 1377 1382 1353 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch1</italic>
###xml 1387 1391 1363 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sfrp</italic>
###xml 1461 1468 1433 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel E</italic>
###xml 1475 1479 1447 1451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sfrp</italic>
###xml 1481 1492 1453 1464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">both panels</italic>
###xml 1498 1503 1470 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch2</italic>
###xml 1505 1512 1477 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel E</italic>
###xml 1584 1585 1556 1557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 9 1633 9 1605 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="54"><bold>Transcriptional activity of GLI1&#916;N on target genes.</bold> The FLAG-tagged pCMV5 GLI1 constructs were co-transfected with <italic>Ptch1</italic>-1B-luc (<italic>A</italic>), <italic>PTCH2</italic>-luc (<italic>B</italic>), or <italic>IL1R2</italic>-luc (<italic>C</italic>) reporter constructs in NIH3T3 cells. pRL-SV was also co-transfected as an internal control. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant except when 25 ng of GLI1 construct was used in <italic>panels B</italic> and <italic>C</italic> (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test). <italic>D</italic> and <italic>E</italic>, up-regulation of endogenous gene expression by GLI1&#916;N and GLI1FL. The FLAG-tagged pCMV5 GLI1 constructs or the empty pCMV5 vector were co-transfected with pcDNA3.1His into NIH3T3 or C3H10T1/2 cells. One day after transfection, the culture medium was changed to Dulbecco's modified Eagle's medium including 10% fetal bovine serum and 0.6 mg/ml G418 (GLI1FL and GLI1&#916;N), with or without the addition of 100 n<sc>m</sc> SAG (pCMV5), and then the cells were incubated for 2 days. Expression of the <italic>Ptch1, Ptch2, Gli1</italic>, and <italic>Sfrp</italic> genes was measured by real-time RT-PCR using SYBR Green. Data are presented as relative Ct values (&#916;Ct), which is the Ct of the target genes minus the Ct of the housekeeping gene <italic>Arp</italic>. The <italic>error bars</italic> indicate the standard deviation. The differences between the &#916;Ct values were statistically significant except when the <italic>Ptch1</italic> and <italic>Sfrp</italic> expression was analyzed following GLI1FL or GLI1&#916;N transfection (<italic>panel E</italic>), and <italic>Sfrp</italic> (<italic>both panels</italic>) and <italic>Ptch2</italic> (<italic>panel E</italic>) expression was analyzed following pCMV transfection or SAG treatment (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test).</p>
###xml 9 1633 9 1605 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="54"><bold>Transcriptional activity of GLI1&#916;N on target genes.</bold> The FLAG-tagged pCMV5 GLI1 constructs were co-transfected with <italic>Ptch1</italic>-1B-luc (<italic>A</italic>), <italic>PTCH2</italic>-luc (<italic>B</italic>), or <italic>IL1R2</italic>-luc (<italic>C</italic>) reporter constructs in NIH3T3 cells. pRL-SV was also co-transfected as an internal control. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant except when 25 ng of GLI1 construct was used in <italic>panels B</italic> and <italic>C</italic> (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test). <italic>D</italic> and <italic>E</italic>, up-regulation of endogenous gene expression by GLI1&#916;N and GLI1FL. The FLAG-tagged pCMV5 GLI1 constructs or the empty pCMV5 vector were co-transfected with pcDNA3.1His into NIH3T3 or C3H10T1/2 cells. One day after transfection, the culture medium was changed to Dulbecco's modified Eagle's medium including 10% fetal bovine serum and 0.6 mg/ml G418 (GLI1FL and GLI1&#916;N), with or without the addition of 100 n<sc>m</sc> SAG (pCMV5), and then the cells were incubated for 2 days. Expression of the <italic>Ptch1, Ptch2, Gli1</italic>, and <italic>Sfrp</italic> genes was measured by real-time RT-PCR using SYBR Green. Data are presented as relative Ct values (&#916;Ct), which is the Ct of the target genes minus the Ct of the housekeeping gene <italic>Arp</italic>. The <italic>error bars</italic> indicate the standard deviation. The differences between the &#916;Ct values were statistically significant except when the <italic>Ptch1</italic> and <italic>Sfrp</italic> expression was analyzed following GLI1FL or GLI1&#916;N transfection (<italic>panel E</italic>), and <italic>Sfrp</italic> (<italic>both panels</italic>) and <italic>Ptch2</italic> (<italic>panel E</italic>) expression was analyzed following pCMV transfection or SAG treatment (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test).</p></caption>
###xml 1633 1633 1605 1605 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0250838450008"/>
###xml 0 1633 0 1605 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig8"><label>FIGURE 8.</label><caption><p textid="54"><bold>Transcriptional activity of GLI1&#916;N on target genes.</bold> The FLAG-tagged pCMV5 GLI1 constructs were co-transfected with <italic>Ptch1</italic>-1B-luc (<italic>A</italic>), <italic>PTCH2</italic>-luc (<italic>B</italic>), or <italic>IL1R2</italic>-luc (<italic>C</italic>) reporter constructs in NIH3T3 cells. pRL-SV was also co-transfected as an internal control. The <italic>error bars</italic> indicate the standard deviation. The differences between the GLI1FL and GLI1&#916;N values were statistically significant except when 25 ng of GLI1 construct was used in <italic>panels B</italic> and <italic>C</italic> (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test). <italic>D</italic> and <italic>E</italic>, up-regulation of endogenous gene expression by GLI1&#916;N and GLI1FL. The FLAG-tagged pCMV5 GLI1 constructs or the empty pCMV5 vector were co-transfected with pcDNA3.1His into NIH3T3 or C3H10T1/2 cells. One day after transfection, the culture medium was changed to Dulbecco's modified Eagle's medium including 10% fetal bovine serum and 0.6 mg/ml G418 (GLI1FL and GLI1&#916;N), with or without the addition of 100 n<sc>m</sc> SAG (pCMV5), and then the cells were incubated for 2 days. Expression of the <italic>Ptch1, Ptch2, Gli1</italic>, and <italic>Sfrp</italic> genes was measured by real-time RT-PCR using SYBR Green. Data are presented as relative Ct values (&#916;Ct), which is the Ct of the target genes minus the Ct of the housekeeping gene <italic>Arp</italic>. The <italic>error bars</italic> indicate the standard deviation. The differences between the &#916;Ct values were statistically significant except when the <italic>Ptch1</italic> and <italic>Sfrp</italic> expression was analyzed following GLI1FL or GLI1&#916;N transfection (<italic>panel E</italic>), and <italic>Sfrp</italic> (<italic>both panels</italic>) and <italic>Ptch2</italic> (<italic>panel E</italic>) expression was analyzed following pCMV transfection or SAG treatment (<italic>p</italic> &lt; 0.01, analysis of variance, Bonferroni test).</p></caption><graphic xlink:href="zbc0250838450008"/></fig>
###xml 849 855 <span type="species:ncbi:9913">bovine</span>
FIGURE 8.Transcriptional activity of GLI1DeltaN on target genes. The FLAG-tagged pCMV5 GLI1 constructs were co-transfected with Ptch1-1B-luc (A), PTCH2-luc (B), or IL1R2-luc (C) reporter constructs in NIH3T3 cells. pRL-SV was also co-transfected as an internal control. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant except when 25 ng of GLI1 construct was used in panels B and C (p < 0.01, analysis of variance, Bonferroni test). D and E, up-regulation of endogenous gene expression by GLI1DeltaN and GLI1FL. The FLAG-tagged pCMV5 GLI1 constructs or the empty pCMV5 vector were co-transfected with pcDNA3.1His into NIH3T3 or C3H10T1/2 cells. One day after transfection, the culture medium was changed to Dulbecco's modified Eagle's medium including 10% fetal bovine serum and 0.6 mg/ml G418 (GLI1FL and GLI1DeltaN), with or without the addition of 100 nm SAG (pCMV5), and then the cells were incubated for 2 days. Expression of the Ptch1, Ptch2, Gli1, and Sfrp genes was measured by real-time RT-PCR using SYBR Green. Data are presented as relative Ct values (DeltaCt), which is the Ct of the target genes minus the Ct of the housekeeping gene Arp. The error bars indicate the standard deviation. The differences between the DeltaCt values were statistically significant except when the Ptch1 and Sfrp expression was analyzed following GLI1FL or GLI1DeltaN transfection (panel E), and Sfrp (both panels) and Ptch2 (panel E) expression was analyzed following pCMV transfection or SAG treatment (p < 0.01, analysis of variance, Bonferroni test).
###end p 53
###begin p 54
###xml 0 55 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Transcriptional activity of GLI1&#916;N on target genes.</bold>
###xml 119 124 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch1</italic>
###xml 133 134 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 137 142 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTCH2</italic>
###xml 148 149 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 155 160 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R2</italic>
###xml 166 167 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 265 275 261 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 445 453 437 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panels B</italic>
###xml 458 459 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 461 462 453 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 511 512 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 517 518 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 934 935 918 919 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 1013 1031 997 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch1, Ptch2, Gli1</italic>
###xml 1037 1041 1021 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sfrp</italic>
###xml 1225 1228 1205 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arp</italic>
###xml 1234 1244 1214 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">error bars</italic>
###xml 1368 1373 1344 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch1</italic>
###xml 1378 1382 1354 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sfrp</italic>
###xml 1452 1459 1424 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel E</italic>
###xml 1466 1470 1438 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sfrp</italic>
###xml 1472 1483 1444 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">both panels</italic>
###xml 1489 1494 1461 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ptch2</italic>
###xml 1496 1503 1468 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel E</italic>
###xml 1575 1576 1547 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 840 846 <span type="species:ncbi:9913">bovine</span>
Transcriptional activity of GLI1DeltaN on target genes. The FLAG-tagged pCMV5 GLI1 constructs were co-transfected with Ptch1-1B-luc (A), PTCH2-luc (B), or IL1R2-luc (C) reporter constructs in NIH3T3 cells. pRL-SV was also co-transfected as an internal control. The error bars indicate the standard deviation. The differences between the GLI1FL and GLI1DeltaN values were statistically significant except when 25 ng of GLI1 construct was used in panels B and C (p < 0.01, analysis of variance, Bonferroni test). D and E, up-regulation of endogenous gene expression by GLI1DeltaN and GLI1FL. The FLAG-tagged pCMV5 GLI1 constructs or the empty pCMV5 vector were co-transfected with pcDNA3.1His into NIH3T3 or C3H10T1/2 cells. One day after transfection, the culture medium was changed to Dulbecco's modified Eagle's medium including 10% fetal bovine serum and 0.6 mg/ml G418 (GLI1FL and GLI1DeltaN), with or without the addition of 100 nm SAG (pCMV5), and then the cells were incubated for 2 days. Expression of the Ptch1, Ptch2, Gli1, and Sfrp genes was measured by real-time RT-PCR using SYBR Green. Data are presented as relative Ct values (DeltaCt), which is the Ct of the target genes minus the Ct of the housekeeping gene Arp. The error bars indicate the standard deviation. The differences between the DeltaCt values were statistically significant except when the Ptch1 and Sfrp expression was analyzed following GLI1FL or GLI1DeltaN transfection (panel E), and Sfrp (both panels) and Ptch2 (panel E) expression was analyzed following pCMV transfection or SAG treatment (p < 0.01, analysis of variance, Bonferroni test).
###end p 54
###begin title 55
DISCUSSION
###end title 55
###begin p 56
###xml 278 284 270 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 406 407 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 412 413 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 403 413 391 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">5, <italic>B</italic> and <italic>C</italic></xref>
###xml 418 421 406 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;D</italic>
###xml 415 421 403 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">8, <italic>A&#8211;D</italic></xref>
###xml 586 587 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 580 587 564 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8<italic>E</italic></xref>
###xml 760 761 740 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 759 761 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">5<italic>D</italic></xref>
###xml 766 767 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">7</xref>
###xml 1010 1012 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 1014 1016 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
###xml 1284 1290 1260 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 36 41 <span type="species:ncbi:9606">human</span>
In this report, we identified novel human GLI1 splice variants that skip exons 2 and 3, resulting in the production of an N-terminal truncated protein isoform, GLI1DeltaN. Similarly to the full-length GLI1, GLI1FL, the generation of GLI1DeltaNis also dependent on HH signaling (Fig. 3). Both GLI1 isoforms can act as transcription factors, with GLI1FL being generally more potent than GLI1DeltaN (Figs. 5, B and C, 8, A-D, and supplemental Fig. S2). However, in C3H10T1/2 cells the activation capacity of GLI1DeltaN on endogenous genes may be more pronounced than that of GLI1FL (Fig. 8E). Moreover, GLI1DeltaN and GLI1FL are under distinct cellular controls, as exemplified by the differential effects of SUFU and the Dyrk1 kinase on their activities (Figs. 5D and 7). Interestingly, GLI1FL is found to be localized in the nucleus, in contrast to previous reports that predominantly detected it in the cytoplasm. This may be due, at least in part, to the fact that a bulky EGFP tag was used in these studies (27, 29). Additionally, the generally higher GLI1FL activity relative to GLI1DeltaN correlates with nuclear localization, and the GLI1 inhibitory effects of SUFU and PTCH1 with cytoplasmic sequestration. Finally, the stronger SUFU inhibition and cytoplasmic shifts of GLI1FL versus GLI1DeltaN are apparently due to the lack of a SUFU binding domain in the latter isoform.
###end p 56
###begin p 57
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref40">40</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref41">41</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref42">42</xref>
###xml 394 400 390 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 881 883 877 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref43">43</xref>
GLI1 and its paralogue GLI2 recognize and bind to the same DNA sequences and activate transcription (40, 41). However, although the target genes of GLI1 and GLI2 do overlap, there is not a complete identity (42). Similarly, although GLI1DeltaN contains the same DNA binding domain as GLI1FL, each isoform appears to be characterized by a partially independent target gene activation mechanism (Fig. 8). This finding strengthens the notion that alternative splicing may be a biological process, in addition to gene duplication, that is able to increase the functional diversity of gene products. In fact, in the Wnt signaling pathway, which antagonizes HH signaling, there are four transcription factors, the TCF/LEF paralogues, capable of generating a number of splice variants, and this diversity is functionally important for mediating tissue- and stage-specific Wnt regulation (43). Thus in the HH and Wnt developmental pathways, splicing variations in the terminal transcription factors may represent an effective means for achieving a highly regulated biological cross-talk.
###end p 57
###begin p 58
###xml 91 97 87 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 214 220 210 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
SAG treatment elicited a nearly equal increase of the GLI1DeltaN transcripts as of GLI1FL (Fig. 3). On the other hand the expression ratios of the two GLI1 isoforms varied greatly in the tumor cell lines analyzed (Fig. 2). The GLI1FL/GLI1DeltaN ratio tends to be high in cells derived from lung carcinoma, but is significantly lower in cells from rhabdomyosarcoma. This suggests that the expression of the GLI1 isoforms may also be actively controlled by factors other than the ones implicated in HH signaling.
###end p 58
###begin p 59
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 9.</label>
###xml 9 94 9 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Model for regulation of expression and transcriptional activity of the GLI1 variants.</bold>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 179 185 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 228 229 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 463 464 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y</italic>
###xml 535 545 531 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Red arrows</italic>
###xml 678 689 674 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green arrow</italic>
###xml 695 712 691 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">long black arrows</italic>
###xml 760 770 756 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line width</italic>
###xml 778 781 774 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 790 807 786 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">long black arrows</italic>
###xml 9 859 9 855 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="60"><bold>Model for regulation of expression and transcriptional activity of the GLI1 variants.</bold> Hedgehog signaling increases the transcription of both GLI1FL (<italic>blue</italic>) and GLI1&#916;N(<italic>yellow</italic>), with additional factors, exemplified by <italic>X</italic>, having a role in balancing their expression levels. The subcellular localization and the capacity of the two isoforms to regulate transcription are controlled by SUFU, PTCH1, and the Dyrk1 kinase, with other factors, exemplified by <italic>Y</italic>, also modulating the specificity of their transcriptional activities. <italic>Red arrows</italic> indicate inhibitory effects on the GLI1 nuclear accumulation and/or the GLI1 activity, whereas a stimulatory effect is shown by the <italic>green arrow</italic>. The <italic>long black arrows</italic> indicate transport to or from the nucleus. The <italic>line width</italic> of the <italic>red</italic> and the <italic>long black arrows</italic> represents the relative intensity of these effects.</p>
###xml 9 859 9 855 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="60"><bold>Model for regulation of expression and transcriptional activity of the GLI1 variants.</bold> Hedgehog signaling increases the transcription of both GLI1FL (<italic>blue</italic>) and GLI1&#916;N(<italic>yellow</italic>), with additional factors, exemplified by <italic>X</italic>, having a role in balancing their expression levels. The subcellular localization and the capacity of the two isoforms to regulate transcription are controlled by SUFU, PTCH1, and the Dyrk1 kinase, with other factors, exemplified by <italic>Y</italic>, also modulating the specificity of their transcriptional activities. <italic>Red arrows</italic> indicate inhibitory effects on the GLI1 nuclear accumulation and/or the GLI1 activity, whereas a stimulatory effect is shown by the <italic>green arrow</italic>. The <italic>long black arrows</italic> indicate transport to or from the nucleus. The <italic>line width</italic> of the <italic>red</italic> and the <italic>long black arrows</italic> represents the relative intensity of these effects.</p></caption>
###xml 859 859 855 855 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0250838450009"/>
###xml 0 859 0 855 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig9"><label>FIGURE 9.</label><caption><p textid="60"><bold>Model for regulation of expression and transcriptional activity of the GLI1 variants.</bold> Hedgehog signaling increases the transcription of both GLI1FL (<italic>blue</italic>) and GLI1&#916;N(<italic>yellow</italic>), with additional factors, exemplified by <italic>X</italic>, having a role in balancing their expression levels. The subcellular localization and the capacity of the two isoforms to regulate transcription are controlled by SUFU, PTCH1, and the Dyrk1 kinase, with other factors, exemplified by <italic>Y</italic>, also modulating the specificity of their transcriptional activities. <italic>Red arrows</italic> indicate inhibitory effects on the GLI1 nuclear accumulation and/or the GLI1 activity, whereas a stimulatory effect is shown by the <italic>green arrow</italic>. The <italic>long black arrows</italic> indicate transport to or from the nucleus. The <italic>line width</italic> of the <italic>red</italic> and the <italic>long black arrows</italic> represents the relative intensity of these effects.</p></caption><graphic xlink:href="zbc0250838450009"/></fig>
FIGURE 9.Model for regulation of expression and transcriptional activity of the GLI1 variants. Hedgehog signaling increases the transcription of both GLI1FL (blue) and GLI1DeltaN(yellow), with additional factors, exemplified by X, having a role in balancing their expression levels. The subcellular localization and the capacity of the two isoforms to regulate transcription are controlled by SUFU, PTCH1, and the Dyrk1 kinase, with other factors, exemplified by Y, also modulating the specificity of their transcriptional activities. Red arrows indicate inhibitory effects on the GLI1 nuclear accumulation and/or the GLI1 activity, whereas a stimulatory effect is shown by the green arrow. The long black arrows indicate transport to or from the nucleus. The line width of the red and the long black arrows represents the relative intensity of these effects.
###end p 59
###begin p 60
###xml 0 85 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Model for regulation of expression and transcriptional activity of the GLI1 variants.</bold>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 170 176 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 219 220 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X</italic>
###xml 454 455 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y</italic>
###xml 526 536 522 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Red arrows</italic>
###xml 669 680 665 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green arrow</italic>
###xml 686 703 682 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">long black arrows</italic>
###xml 751 761 747 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">line width</italic>
###xml 769 772 765 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 781 798 777 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">long black arrows</italic>
Model for regulation of expression and transcriptional activity of the GLI1 variants. Hedgehog signaling increases the transcription of both GLI1FL (blue) and GLI1DeltaN(yellow), with additional factors, exemplified by X, having a role in balancing their expression levels. The subcellular localization and the capacity of the two isoforms to regulate transcription are controlled by SUFU, PTCH1, and the Dyrk1 kinase, with other factors, exemplified by Y, also modulating the specificity of their transcriptional activities. Red arrows indicate inhibitory effects on the GLI1 nuclear accumulation and/or the GLI1 activity, whereas a stimulatory effect is shown by the green arrow. The long black arrows indicate transport to or from the nucleus. The line width of the red and the long black arrows represents the relative intensity of these effects.
###end p 60
###begin p 61
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 279 280 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 126 131 <span type="species:ncbi:9606">human</span>
###xml 147 152 <span type="species:ncbi:10090">mouse</span>
###xml 262 267 <span type="species:ncbi:9606">human</span>
###xml 272 277 <span type="species:ncbi:10090">mouse</span>
###xml 673 678 <span type="species:ncbi:10090">mouse</span>
###xml 690 695 <span type="species:ncbi:9606">human</span>
In similarity with the PTCH1-1Ckid mRNA variant characterized previously (16), the GLI1DeltaN splice form was detected in the human but not in the mouse. Recent reports indicate that only 10-20% of cassette-type alternative splicing events are conserved between human and mouse (3). It is not yet clear what the implications of these differences in splicing variations among species may be. However, splice variants have the potential to encode a larger variety of functionally different proteins than gene paralogues. It may therefore be important to pay attention to a possible influence of alternative transcription and alternative splicing in the context of developing mouse models for human diseases.
###end p 61
###begin p 62
###xml 164 170 164 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig9" ref-type="fig">Fig. 9</xref>
###xml 332 333 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">2</xref>
###xml 338 339 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">3</xref>
###xml 471 472 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 470 472 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">5<italic>D</italic></xref>
###xml 477 478 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">7</xref>
###xml 510 516 502 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
In summary our findings reveal an increased complexity in the activation process of the terminal effector of HH signaling, GLI1, and are summarized in the model of Fig. 9. GLI1DeltaN and GLI1FL transcripts are up-regulated not only by HH signaling but also additional factors play a role in balancing their expression levels (Figs. 2 and 3). Moreover, the transcriptional capacity of GLI1DeltaN and GLI1FL is differentially regulated by SUFU and the Dyrk1 kinase (Figs. 5D and 7). Additionally, other factors (Fig. 8) are also likely to influence the gene activation properties of the two GLI1 isoforms.
###end p 62
###begin title 63
Supplementary Material
###end title 63
###begin title 64
[Supplemental Data]
###end title 64
###begin p 65
We thank Drs. Fritz Aberger (University of Salzburg), Priit Kogerman (Tallinn Technical University), and Marie Fiaschi, Fahimeh Rahnama, and Stephan Teglund (Karolinska Institute) for reporter and expression plasmids. We are grateful to B. Lindqvist, C. Finta, V. Jaks, and A. Bergstrom for helpful discussions and technical support.
###end p 65
###begin p 66
The abbreviations used are: HH, hedgehog; GLI1, Glioma-associated oncogene 1; GLI1FL, full-length GLI1; GLI1DeltaN, GLI1 with skipped exons 2 and 3; SMO, Smoothened; SUFU, Suppressor of Fused; PTCH, Patched; Dyrk1, dual-specificity tyrosine phosphorylation-regulated kinase 1; SAG, SMO agonist; GANT, Gli antagonist; GLIBS, GLI-binding site; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RPLP0, ribosomal protein large P0; Arp, acidic ribosomal protein; IL1R2, interleukin 1 receptor, type II; Sfrp, secreted frizzled-related protein; EGFP, enhanced green fluorescent protein; RT, reverse transcriptase.
###end p 66
###begin p 67
T. Shimokawa, U. Tostar, M. Lauth, R. Palaniswamy, M. Kasper, R. Toftgard, and P. G. Zaphiropoulos, unpublished data.
###end p 67
###begin p 68
M. Lauth, unpublished data.
###end p 68

